STOCK DOWN 8%: WHAT'S BEHIND TEVA'S MASSIVE PLUNGE?
Teva sells Copaxone. Teva's Copaxone patent is expiring in 2014! The clock on Copaxone's market exclusivity is ticking fast! Plus: New competitors in the multiple sclerosis treatment market, such as Tecfidera, are another threat to Copaxone sales. Today, Teva's future is even more uncertain after its CEO announced his resignation.
Click here to see
